Investor Presentaiton

Respiratory diagnostics are failing us Spirometry: 1846 1D technology Accurate but insensitive 20% market Cost EME SPIROMET 108 VQ Scan: USD $1,503 (Average estimated) Advantages: Perfusion analysis capability; Only modality that can identify ventilation-perfusion mismatch; Importance in treating pulmonary embolism & hypertension 49-50 51-52 Limitations: ⚫ High cost, poor resolution of outputs ⚫ Time consuming (1 hour to complete) 1 49-50 51-52 53- • Use of dual radioactive particulate contrast agents raises toxicity concerns, Expensive testing equipment needed 4DMedical™ X-ray: 1895 2D technology Inexpensive, but tells us very little about airflow 67% market Nuclear Medicine: 1971 3D technology Measures both ventilation and perfusion, but has significant limitations 1% market Complex to administer, requires expert analysis, onerous safety precautions These four technologies account for 99% of the 382 million respiratory diagnostics test performed per annum globally 4DMedical Limited (ASX:4DX) Investor Presentation | July 2022 11

View entire presentation